News | April 01, 2015

Variations in Use of Physician Preference Items Affect Patient Outcomes and Costs

Study finds medical devices going unused, physicians ordering devices that don’t match patient indications

April 1, 2015 — UHC has released the findings of a new study that evaluated the use of medical devices based on cost and quality outcomes. The goal of the study was to uncover several trends related to high-priced physician preference items (PPIs). Utilization of PPIs — which can account for 30 to 40 percent of a hospital's supply expenses — at 10 academic medical centers, focusing on procedures utilizing orthopedic implants, coronary and peripheral stents and cardiac valves.

The study, begun in 2013, integrated the pilot test of the UHC Supply Cost & Quality Tool, a business intelligence tool designed to help healthcare organizations identify variations in the use of medical devices and their links to costs and patient outcomes. The study identified the following trends:

  • "Custom" does not always mean quality: One organization identified a surgeon who routinely used a customized hip implant for patients undergoing standard, elective total hip replacement. The price tag for the customized implant alone was higher than the average Medicare reimbursement for the entire hospital stay. This physician's patients also had longer hospital stays, on average, and higher readmission rates than those of other physicians.
  • Hidden waste in unused devices: An analysis at one hospital showed that one of its physicians was wasting an average of $600 per hip implant procedure—six times more than other physicians at the hospital—as a result of opened but unused implants.
  • Not all devices match every patient: At one organization, physicians were consistently using hip implant components for older patients that were more advanced than those used for younger patients, counter to published research showing that standard components are more clinically appropriate for less-active patients. The costs of the advanced components were usually at least 25 percent higher than those of standard components.

 

"Our study reinforces that there is a clear need for healthcare organizations to have an integrated view of supply costs and patient outcomes in resource-intensive areas, such as orthopedic and cardiovascular care," said Mike Oinonen, senior director, CDI operations, product technology, UHC. "By leveraging data from UHC's supply chain and clinical databases, along with utilization data from their clinical systems, the study participants identified significant opportunities to reduce clinical variation, strengthen contract negotiations with suppliers, improve product selection and minimize product waste."

Following the pilot project, UHC released the Supply Cost & Quality Tool to its membership; UHC members that subscribe to the Clinical Data Base/Resource Manager and SpendLINK are eligible to participate in the tool. 

The case examples in the paper were derived from a very limited data sample from organizations that participated in the Supply Cost & Quality Tool pilot project. UHC plans to develop benchmark data while expanding into additional clinical areas as more participants use the tool.  

For more information: www.uhc.edu

Related Content

Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab | November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab | November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab | November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Overlay Init